Home Latest Articles
Latest Articles
  • Huahua HUANG, Jinghai CHEN, Yali YANG, Liping ZENG, Nating HUANG, Xuezi HE
    Chinese Journal of Pharmaceuticals. 2026, 57(2): 199-203.

    To reduce the dosage size, response surface methodology was employed to optimize the formulation of rhubarb sodium bicarbonate tablets using rhubarb extract as the raw material. A comprehensive score, based on weight variation, friability, disintegration time, granule yield, and total anthraquinone content of rhubarb, was adopted as the evaluation indicator. The dosages of wetting agent, disintegrant, and lubricant were optimized and confirmed as follows:wetting agent(60% of ethanol) at 2.9 mL, disintegrant(sodium carboxymethyl starch) at 4.0%, and lubricant(magnesium stearate) at 1.2%. Three batches of tablets were prepared according to the optimized formulation, with an average total anthraquinone content of 24.466 5 mg/g, accounting for 96.42% of that in the original rhubarb extract. The optimized process not only reduces the dosage size but also minimizes the loss of active ingredients, showing reliable stability. This study provides valuable references for standardizing the manufacturing process and quality control of rhubarb sodium bicarbonate tablets.

  • Cihui TIAN, Xiaohua ZHANG, Dan XU
    Chinese Journal of Pharmaceuticals. 2026, 57(2): 204-210.

    By using the accelerated stability assessment program(ASAP), the impact of residual moisture of olmesartan medoxomil(1) tablets on stability was predicted to optimize the manufacturing process. A temperature-humidity-time matrix experiment was designed using the ASAPprime® software, and the degradation rate of 1 was accelerated via short-term extreme condition experiments. The content of olmesartan acid(impurity A) was detected by HPLC, and a degradation kinetic model of 1 was established to predict the effects of different residual moisture levels on stability. The results showed that the fitted degradation kinetic model had a high humidity factor (B>0.04), indicating that 1 tablets were moisture-sensitive. Based on the modeling results, the coating drying time was adjusted to no less than 20 min to ensure that the final product moisture content did not exceed 1.65%. The measured values of impurity A in the optimal tablets stored under long-term storage conditions[(30±2)℃ and relative humidity (65±5)%] were close to the model predictions. This study suggests that the application of ASAP can significantly shorten the drug stability study period and provide a basis for process optimization and quality control in pharmaceutical formulation development.

  • Guizhou HAO, Zehua HAO, Ping SU, Futing LI, Jing LIU, Honghua LU
    Chinese Journal of Pharmaceuticals. 2026, 57(2): 211-214.

    A GC-MS method was established for the determination of 1,6-dibromohexane(2), ethyl 8-bromooctanoate(3), and diethyl 2-(6-bromohexyl) malonate(4) in sodium 8-(2-hydroxybenzamido) octanoate(SNAC), an absorption enhancer in oral semaglutide formulations. These three haloalkanes contain alerting structures and pose potential carcinogenic risks. A DB-5ms capillary column was used, and selected ion monitoring mode(SIM) was adopted for quantitative analysis. The results showed good linear relationships between peak area and mass concentration in the ranges of 20 - 120 ng/mL for impurity 2, 20 - 120 ng/mL for impurity 3, and 22 - 130 ng/mL for impurity 4. The limits of quantification were 1.003 ng/mL for 2, 3.296 ng/mL for 3 and 0.544 ng/mL for 4. And their average recoveries ranged from 98.2% to 102.2%. Among three batches of SNAC samples, impurities 2 and 4 were not detected, and the level of impurity 3 was below the limit(5×10–6).

  • Ying KANG, Yansong MA, Fang DONG, Yimeng ZHOU
    Chinese Journal of Pharmaceuticals. 2026, 57(2): 216-221.
  • Yansong MA, Ziyang CAI, Jianing YU, Ruoxi YAN
    Chinese Journal of Pharmaceuticals. 2026, 57(2): 222-229.
  • Fang DONG, Yansong MA, Ying KANG, Yimeng ZHOU
    Chinese Journal of Pharmaceuticals. 2026, 57(2): 230-235.
  • Hui LI, Fufang TAO, Sijin WANG, Jinfang SHENG, Shihong MA
    Chinese Journal of Pharmaceuticals. 2026, 57(2): 236-242.
  • Fan ZHANG, Yunrui DI, Hao YANG, Zhenyu XU
    Chinese Journal of Pharmaceuticals. 2026, 57(2): 243-248.
  • Hailong HU, Yun ZHANG, Xuejun QIU, Xu YANG, Feilong ZHU
    Chinese Journal of Pharmaceuticals. 2026, 57(2): 249-256.
  • Jiahui WANG, Bo HAN, Zixue ZHANG, Qingwei ZHANG
    Chinese Journal of Pharmaceuticals. 2026, 57(1): 1-28.

    In 2025, FDA approved 46 new drugs for marketing, including 31 small molecule drugs and 15 biological products. Based on FDA-approved drug labeling, related databases, patents, and published literature, this review describes the chemical name, original research company, compound patent, time to market, indications, mechanism of action, dosage form and strengths, adverse effects and synthesis routes of those small molecule drugs, and the basic information about biological products.

News